Cognision has entered a strategic partnership with SOMNOmedics AG to advance the use of sleep biomarkers in pharmaceutical clinical trials. According to the company, Cognision will supply SOMNOmedics’ next-generation polysomnography (PSG) systems, tailored for use in regulated research environments.
The deal combines Cognision’s experience in delivering neurophysiological biomarkers (such as EEG and event-related potentials) in clinical studies with SOMNOmedics’ compact, mobile, and full-feature PSG equipment. The companies claim the joint offering enables sponsors to capture reliable sleep architecture data in trials of drugs targeting sleep disorders or drugs that may affect sleep.
Under the collaboration, PSG data will be integrated with Cognision’s cloud-based Clinical Trial Data Management System (CTMS), offering sponsor access in near real time. The companies assert this supports faster decision making and adaptive trial designs.
Cognision frames the partnership as reinforcing its position in neurophysiological endpoints in drug development, particularly within CNS (central nervous system) research. SOMNOmedics’ PSG solutions are intended to expand their footprint in pharmaceutical trials, including in decentralized clinical trial settings, where home-use or mobile monitoring may be required.
No financial terms were disclosed.
